Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01531894 | Continuation Study of the Oral AKT Inhibitor GSK2110183 | PHASE2 | COMPLETED | 11 | — | — | Feb 8, 2012 | Jun 20, 2018 | Jul 9, 2019 | 8 | United States, Australia +3 |
Adverse Events (AEs) includes Summary of adverse events, drug related AEs, Serious adverse events, adverse events leading to study treatment discontinuation and death.
| Arm | Type | Description |
|---|---|---|
| GSK2110183 (afuresertib) | EXPERIMENTAL | All patients received the GSK2110183 (afuresertib) treatment |
| Name | Type | Description |
|---|---|---|
| GSK2110183 (afuresertib) | DRUG | Afuresertib is an oral, low nanomolar pan-AKT kinase inhibitor immediate release (IR) 50 mg or 75 mg tablets was to be taken orally with at least 200 mL of water, with or without food, in the morning. |
Inclusion Criteria: * Has provided signed informed consent for this study. * Is currently participating in a GSK2110183 study (monotherapy or in combination with an approved anti-cancer agent) sponsored by GSK or by another research organization working on behalf of GSK. * Currently benefitting fro...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520 / GEH200521 - Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | — | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |